8 reports of this reaction
1.4% of all TITANIUM DIOXIDE reports
#20 most reported adverse reaction
MALIGNANT MELANOMA is the #20 most commonly reported adverse reaction for TITANIUM DIOXIDE, manufactured by Baxter of California, LLC. There are 8 FDA adverse event reports linking TITANIUM DIOXIDE to MALIGNANT MELANOMA. This represents approximately 1.4% of all 566 adverse event reports for this drug.
Patients taking TITANIUM DIOXIDE who experience malignant melanoma should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MALIGNANT MELANOMA is a less commonly reported adverse event for TITANIUM DIOXIDE, but still significant enough to appear in the safety profile.
In addition to malignant melanoma, the following adverse reactions have been reported for TITANIUM DIOXIDE:
The following drugs have also been linked to malignant melanoma in FDA adverse event reports:
MALIGNANT MELANOMA has been reported as an adverse event in 8 FDA reports for TITANIUM DIOXIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
MALIGNANT MELANOMA accounts for approximately 1.4% of all adverse event reports for TITANIUM DIOXIDE, making it a notable side effect.
If you experience malignant melanoma while taking TITANIUM DIOXIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.